Status:
WITHDRAWN
LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia
Lead Sponsor:
Leading BioSciences, Inc
Conditions:
COVID-19
Coronavirus Disease 2019
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a Phase 2, proof of concept, randomized, placebo-controlled, multicenter study to evaluate the ability of LB1148 to attenuate pulmonary dysfunction associated with COVID-19 pneumonia. The prim...
Detailed Description
The purpose of this study is to establish the safety and tolerability, along with preliminary evidence of efficacy, of LB1148 compared to placebo in hospitalized patients with moderate to severe coron...
Eligibility Criteria
Inclusion
- Adult patients (18 years of age or older) with the diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, confirmed via an established standard reverse transcriptase polymerase chain reaction (RT-PCR) assay.
- Patient or patient's legally authorized representative is willing and able to provide informed consent prior to performing any study-related procedures.
- Patient is hospitalized and requires some form of supplemental oxygen, e.g., non-invasive ventilation, high flow oxygen device, or oxygen by mask or nasal cannula.
- Patient has radiographic evidence of pulmonary infiltrate(s) or lung inflammation.
Exclusion
- Participation in any other interventional clinical trial using an experimental treatment (drug or device) for COVID-19.
- Expected survival or time to withdrawal of life-sustaining treatments is expected to be \< 7 days.
- Patients with do not intubate orders.
- Patients who require invasive mechanical ventilation at the time of Screening.
- Patients who require renal replacement therapy (RRT) at the time of Screening.
- Patients with known aspiration problems.
- Has contraindications or potential risk factors to taking TXA. These include patients with:
- Known sensitivity to TXA;
- Recent craniotomy (past 30 days);
- Active cerebrovascular bleed;
- Active thromboembolic disease (such as deep vein thrombosis, pulmonary embolism, cerebral thrombosis, ischemic stroke, or acute coronary syndrome);
- Acute promyelocytic leukemia taking all-trans retinoic acid for remission induction
- Continuing use of a combined hormonal contraceptive and or combined hormonal replacement therapy (including combined hormonal pill, patch, or vaginal ring).
- Concomitant therapy with tissue plasminogen activators, Factor IX complex concentrates or anti-inhibitor coagulant concentrates.
- Known medical history of congenital or acquired thrombophilia such as, but not limited to patients with:
- Sickle cell disease
- Nephrotic syndrome
- Factor V Leiden
- Prothrombin gene mutation
- Protein C or S deficiency
- Antithrombin III deficiency
- Antiphospholipid syndrome
- Patients with myeloproliferative disorders.
- Any other condition that, in the opinion of the treating Investigator, would preclude the patient from being an appropriate candidate for the study.
- Female patients who are pregnant or breastfeeding at the time of Screening.
Key Trial Info
Start Date :
October 31 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04390217
Start Date
October 31 2021
End Date
March 31 2022
Last Update
May 13 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.